Skip to main content
Erschienen in: Journal of Community Health 2/2018

30.08.2017 | Original Paper

U.S. Primary Care Clinics’ Experiences During Introduction of the 9-Valent HPV Vaccine

verfasst von: Melanie L. Kornides, William A. Calo, Jennifer A. Heisler-MacKinnon, Melissa B. Gilkey

Erschienen in: Journal of Community Health | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Changes in the routine immunization schedule are common and may pose challenges to primary care clinics. We sought to assess the experiences of U.S. providers and clinic staff during the introduction of 9-valent HPV vaccine. In 2015–2016, we conducted a survey in a probability sample of 127 pediatric (40%) and family medicine (60%) clinics in three U.S. states. The 211 respondents included clinicians (63%) and staff (37%). Overall, 83% of clinics stocked 9-valent HPV vaccine, with adoption ranging from 60% among early respondents to 100% among later respondents. Almost all respondents believed that providers in their clinics would recommend the 9-valent vaccine as strongly as (66%) or more strongly than (33%) the quadrivalent vaccine. Over half (61%) had no concerns about the 9-valent vaccine, while others reported concerns about increased parental hesitancy (29%), private insurance coverage (17%), or other issues (10%). Respondents from pediatric versus family medicine clinics more often reported a concern (OR = 2.06, 95% CI 1.02–4.15). Among the 169 respondents who stocked 9-valent vaccine, about half (56%, n = 94) anticipated that providers in their clinics would recommend a “booster” dose of 9-valent HPV vaccine for adolescents who had completed the 3-dose series with prior versions. Among the 42 respondents who did not stock 9-valent vaccine, few (17%, n = 7) believed providers would recommend adolescents delay vaccination until it was available. In conclusion, providers and staff generally had positive views of 9-valent HPV vaccine and many had no concerns. For others, responses regarding parental hesitancy, insurance coverage, and the use of booster doses suggests opportunities for enhancing future educational support.
Literatur
1.
Zurück zum Zitat Cohen, N. J., Lauderdale, D. S., Shete, P. B., Seal, J. B., & Daum, R. S. (2003). Physician knowledge of catch-up regimens and contraindications for childhood immunizations. Pediatrics, 111(5), 925–932.CrossRefPubMed Cohen, N. J., Lauderdale, D. S., Shete, P. B., Seal, J. B., & Daum, R. S. (2003). Physician knowledge of catch-up regimens and contraindications for childhood immunizations. Pediatrics, 111(5), 925–932.CrossRefPubMed
3.
Zurück zum Zitat Fontenot, H. B., Domush, V., & Zimet, G. D. (2015). Parental attitudes and beliefs regarding the nine-valent human papillomavirus vaccine. Journal of Adolescent Health, 57(6), 595–600.CrossRefPubMed Fontenot, H. B., Domush, V., & Zimet, G. D. (2015). Parental attitudes and beliefs regarding the nine-valent human papillomavirus vaccine. Journal of Adolescent Health, 57(6), 595–600.CrossRefPubMed
4.
Zurück zum Zitat Markowitz, L. E., Dunne, E. F., Saraiya, M., Lawson, H. W., Chesson, H., & Unger, E. R. (2007). Quadrivalent human papillomavirus vaccine—recommendations of the advisory committee on immunization practices (ACIP). Morbidity and Mortality Weekly Report Recommendations and Reports, 56(RR-2), 1–24.PubMed Markowitz, L. E., Dunne, E. F., Saraiya, M., Lawson, H. W., Chesson, H., & Unger, E. R. (2007). Quadrivalent human papillomavirus vaccine—recommendations of the advisory committee on immunization practices (ACIP). Morbidity and Mortality Weekly Report Recommendations and Reports, 56(RR-2), 1–24.PubMed
5.
Zurück zum Zitat Centers for Disease Control and Prevention (CDC). (2010). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 59(20), 630–632. Centers for Disease Control and Prevention (CDC). (2010). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 59(20), 630–632.
6.
Zurück zum Zitat Petrosky, E., Bocchini, J. A., Hariri, S., Chesson, H., Curtis, C. R., Saraiya, M., et al. (2015). Use of 9-Valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices. Morbidity and Mortality Weekly Report, 64(11), 300–304.PubMedPubMedCentral Petrosky, E., Bocchini, J. A., Hariri, S., Chesson, H., Curtis, C. R., Saraiya, M., et al. (2015). Use of 9-Valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices. Morbidity and Mortality Weekly Report, 64(11), 300–304.PubMedPubMedCentral
7.
Zurück zum Zitat Meites, E., Kempe, A., & Markowitz, L. E. (2016). Use of a 2-dose schedule for human papillomavirus vaccination: Updated recommendations of the advisory committee on immunization practices. Morbidity and Mortality Weekly Report, 65(49), 1405–1408.CrossRefPubMed Meites, E., Kempe, A., & Markowitz, L. E. (2016). Use of a 2-dose schedule for human papillomavirus vaccination: Updated recommendations of the advisory committee on immunization practices. Morbidity and Mortality Weekly Report, 65(49), 1405–1408.CrossRefPubMed
8.
Zurück zum Zitat Markowitz, L. E., Dunne, E. E., Saraiya, M., Chesson, H. W., Curtis, C. R., Gee, J., et al. (2014). Human papillomavirus vaccination recommendations of the advisory committee on immunization practices (ACIP). Morbidity and Mortality Weekly Report Recommendations and Reports, 63(RR-05), 1–30.PubMed Markowitz, L. E., Dunne, E. E., Saraiya, M., Chesson, H. W., Curtis, C. R., Gee, J., et al. (2014). Human papillomavirus vaccination recommendations of the advisory committee on immunization practices (ACIP). Morbidity and Mortality Weekly Report Recommendations and Reports, 63(RR-05), 1–30.PubMed
9.
Zurück zum Zitat Desai, M., & Begg, M. D. (2008). A comparison of regression approaches for analyzing clustered data. American Journal of Public Health, 98(8), 1425–1429.CrossRefPubMedPubMedCentral Desai, M., & Begg, M. D. (2008). A comparison of regression approaches for analyzing clustered data. American Journal of Public Health, 98(8), 1425–1429.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Brewer, N. T., Gottlieb, S. L., Reiter, P. L., McRee, A. L., Liddon, N., Markowitz, L., & Smith, J. S. (2011). Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sexually Transmitted Diseases, 38(3), 197–204.CrossRefPubMedPubMedCentral Brewer, N. T., Gottlieb, S. L., Reiter, P. L., McRee, A. L., Liddon, N., Markowitz, L., & Smith, J. S. (2011). Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sexually Transmitted Diseases, 38(3), 197–204.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Liddon, N. C., Hood, J. E., & Leichliter, J. S. (2012). Intent to receive HPV vaccine and reasons for not vaccinating among unvaccinated adolescent and young women: Findings from the 2006–2008 National Survey of Family Growth. Vaccine, 30(16), 2676–2682.CrossRefPubMed Liddon, N. C., Hood, J. E., & Leichliter, J. S. (2012). Intent to receive HPV vaccine and reasons for not vaccinating among unvaccinated adolescent and young women: Findings from the 2006–2008 National Survey of Family Growth. Vaccine, 30(16), 2676–2682.CrossRefPubMed
12.
Zurück zum Zitat Gilkey, M. B., Moss, J. L., Coyne-Beasley, T., Hall, M. E., Shah, P. D., & Brewer, N. T. (2015). Physician communication about adolescent vaccination: How is human papillomavirus vaccine different? Preventive Medicine, 77, 181–185.CrossRefPubMedPubMedCentral Gilkey, M. B., Moss, J. L., Coyne-Beasley, T., Hall, M. E., Shah, P. D., & Brewer, N. T. (2015). Physician communication about adolescent vaccination: How is human papillomavirus vaccine different? Preventive Medicine, 77, 181–185.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Kasting, M. L., Wilson, S., Dixon, B. E., Downs, S. M., Kulkarni, A., & Zimet, G. D. (2016). A qualitative study of healthcare provider awareness and informational needs regarding the nine-valent HPV vaccine. Vaccine, 34(11), 1331–1334.CrossRefPubMedPubMedCentral Kasting, M. L., Wilson, S., Dixon, B. E., Downs, S. M., Kulkarni, A., & Zimet, G. D. (2016). A qualitative study of healthcare provider awareness and informational needs regarding the nine-valent HPV vaccine. Vaccine, 34(11), 1331–1334.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Healy, C. M., Montesinos, D. P., & Middleman, A. B. (2014). Parent and provider perspectives on immunization: Are providers overestimating parental concerns? Vaccine, 32(5), 579–584.CrossRefPubMed Healy, C. M., Montesinos, D. P., & Middleman, A. B. (2014). Parent and provider perspectives on immunization: Are providers overestimating parental concerns? Vaccine, 32(5), 579–584.CrossRefPubMed
15.
Zurück zum Zitat Farmar, A.-L. M., Love-Osborne, K., Chichester, K., Breslin, K., Bronkan, K., & Hambidge, S. J. (2016). Achieving high adolescent HPV vaccination coverage. Pediatrics, 138(5), e20152653.CrossRefPubMed Farmar, A.-L. M., Love-Osborne, K., Chichester, K., Breslin, K., Bronkan, K., & Hambidge, S. J. (2016). Achieving high adolescent HPV vaccination coverage. Pediatrics, 138(5), e20152653.CrossRefPubMed
17.
Zurück zum Zitat Conroy, K., Rosenthal, S. L., Zimet, G. D., Jin, Y., Bernstein, D. I., Glynn, S., & Kahn, J. A. (2009). Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. Journal of Womens Health, 18(10), 1679–1686.CrossRef Conroy, K., Rosenthal, S. L., Zimet, G. D., Jin, Y., Bernstein, D. I., Glynn, S., & Kahn, J. A. (2009). Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. Journal of Womens Health, 18(10), 1679–1686.CrossRef
18.
Zurück zum Zitat Schluterman, N. H., Terplan, M., Lydecker, A. D., & Tracy, J. K. (2011). Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital. Vaccine, 29(21), 3767–3772.CrossRefPubMed Schluterman, N. H., Terplan, M., Lydecker, A. D., & Tracy, J. K. (2011). Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital. Vaccine, 29(21), 3767–3772.CrossRefPubMed
Metadaten
Titel
U.S. Primary Care Clinics’ Experiences During Introduction of the 9-Valent HPV Vaccine
verfasst von
Melanie L. Kornides
William A. Calo
Jennifer A. Heisler-MacKinnon
Melissa B. Gilkey
Publikationsdatum
30.08.2017
Verlag
Springer US
Erschienen in
Journal of Community Health / Ausgabe 2/2018
Print ISSN: 0094-5145
Elektronische ISSN: 1573-3610
DOI
https://doi.org/10.1007/s10900-017-0420-x

Weitere Artikel der Ausgabe 2/2018

Journal of Community Health 2/2018 Zur Ausgabe